Retroviral insertions that activate proto-oncogenes are a primary cause of tumors in certain strains of mice. The AKXD recombinant inbred mice are predisposed to a variety of leukemias and lymphomas as a result of viral integration. One common insertion site, the ecotropic viral insertion site 3 (Evi3), has been implicated in most B-cell tumors in the AKXD-27 strain. The Evi3 gene encodes a zinc-finger protein with sequence similarity to the Early B-cell Factor-Associated Zinc-finger gene (EBFAZ). We show that the Evi3 gene is overexpressed in several tumors with viral insertions at Evi3, which results in the upregulation of Early B-cell Factor (EBF)-target gene expression, suggesting that Evi3 modulates EBF activity. Reconstitution of primary leukemia cells showed that these tumors express high densities of the Bcell surface proteins CD19 and CD38, which are EBF targets. Using a transactivation assay, we show that the terminal six zinc-fingers of Evi3 are required for modification of EBF activity. This is the first evidence that Evi3 expression in tumors alters the level of EBF target genes, and the first characterization of the Evi3 protein domains required for modulation of EBF activity. Further, these data imply that Evi3 misexpression initiates tumorigenesis by perturbing B-cell development via an interaction with EBF.
Introduction
The AKXD recombinant inbred strains of mice are a valuable system for the study of the molecular genetic basis for the development of leukemia and lymphoma (Mucenski et al., 1986 (Mucenski et al., , 1987 (Mucenski et al., , 1988 Gilbert et al., 1993) . These mice develop a variety of B-cell and T-cell lymphomas and leukemias due to somatic proviral insertions that alter gene expression of proto-oncogenes or tumor suppressor genes. The integrated provirus can serve as a tag to clone novel genes involved in the leukemia or lymphoma disease process. The AKXD mouse strains are valuable for identifying new genes that lead to the development of B-lineage tumors (Mucenski et al., 1987; Justice et al., 1994; Hansen et al., 2000; Suzuki et al., 2002) .
If independent tumors from different mice have proviral insertions at the same genomic site, then it is likely that the region flanking the insertion contains a proto-oncogene. Thus, the identification of common sites of viral insertion is likely to identify genes responsible for oncogenesis. One common proviral insertion site identified from AKXD B-cell tumors is the ecotropic viral insertion site 3 (Evi3) (Justice et al., 1994) . In the AKXD-27 recombinant inbred strain of mice, 70% (seven of 10) of pre-B and B-cell tumors contained proviral insertions at Evi3, whereas no T-cell or myeloid tumors contained insertions, indicating that insertions at Evi3 cause tumors of the B-cell lineage (Justice et al., 1994) .
Evi3 is located on proximal mouse chromosome 18 in a region of homology to human chromosome 18q12 (Justice et al., 1994) . Cloning of mouse genomic DNA revealed that Evi3 lies within a CpG island, indicating that the proviral insertions were likely near the promoter or 5 0 end of a gene (Justice et al., 1994) . Northern blots with the Evi3 insertion site genomic probe identified transcripts that are expressed in developing B-cells, but not mature B-cells, suggesting that the gene encoded at Evi3 may play a role in B-cell differentiation or survival (Justice et al., 1994) .
The gene encoded at Evi3 is a novel multiple zincfinger-containing protein (Warming et al., 2003) with similarity to Early B-cell Factor-Associated Zinc-finger (EBFAZ/ROAZ/OAZ) (Tsai and Reed, 1998; Hata et al., 2000) . EBFAZ has been demonstrated to modulate the transcriptional activation activity of Olf-1/EBF, a helix-loop-helix transcription factor identified as a regulator of both B-cell development and olfactory neuron differentiation Wang et al., 1997) . Here, we analyse the expression of Evi3, as well as a number of Early B-cell Factor (EBF) target genes in tumors with proviral insertions at Evi3. We also determine the immunophenotype of reconstituted primary tumor cells to show that EBF target genes are highly expressed on the surface of tumor cells with Evi3 insertions. Together, our data suggest that activation of EBF target genes leads to leukemia. Further investigation of the role of Evi3 during normal B-cell development and in B-cell tumors will provide clues as to how this gene functions during oncogenesis.
Results

Tumors that arise in the AKXD-27 strain
To obtain additional primary tumor samples with retroviral insertions at Evi3, we aged mice from the AKXD-27 strain, a strain that had previously shown a high predominance of tumors with insertions at Evi3. Previous studies of lymphoma susceptibility in AKXD mice evaluated only females. To address the possibility of differences in male versus female lymphoma susceptibility, approximately equal numbers of male and female mice were aged. In all, 31 of 40 female mice (77.5%) developed tumors, whereas 10 of 34 male mice (29%) developed tumors. This number is significantly different from the expected value (w 2 ; Po0.05), and suggests a sex bias towards tumor development in AKXD-27 female mice. This sex-specific bias was not observed in other AKXD strains (data not shown).
Tumors that arise in AKXD-27 mice were classified by antigen receptor rearrangements and histopathology (Table 1) . We found a diverse array of lymphoid tumors based upon BCR (IgH and/or Igk) and TCR (Jb1 or Jb2) rearrangements. We classified tumors with IgH, but not Igk rearrangements as pro-B-cell tumors, and those with rearrangements of IgH and Igk as pre-B-cell tumors (Mucenski et al., 1988) . Of the B lineage tumors identified, only three had rearrangements at the Igk locus, suggesting that most of these immature B-lineage tumors arise in the bone marrow. In the present study, B-cell lineage tumors were found in 70% of the total tumors examined. Eight tumors harbored retroviral insertions at Evi3, an insertion site that has been frequently observed in AKXD-27 B-cell tumors (Justice et al., 1994) . Seven of these were classified as pro-B-cell tumors, whereas one tumor had no TCR or BCR rearrangements, and is classified as a progenitor tumor by histopathology (H Morse, personal communication). All Evi3 proviral insertions occurred in female mice.
Analysis of the Evi3 gene
We identified and sequenced two IMAGE clones (www.image. llnl.gov, #5359310 and #5038671) that contained Evi3 transcript sequence. Analysis of the two sequences revealed that the IMAGE clone #5359310 (Genbank #BI730849) insert contains a longer 3 0 UTR, but the same predicted open reading frame as IMAGE clone #5038671 (Genbank #BC021376). The IMAGE clone #5359310 complete insert sequence is 6033 bp, compared with 4781 bp for IMAGE clone #5038671. The Evi3 gene cDNA sequence identified by Warming et al. (2003) , Genbank #AY147406, also lacks the longer 3 0 UTR identified from our sequencing of the IMAGE clone #5359310.
The proviral insertions at Evi3 have been localized to the first intron of the Evi3 gene (Figure 1a) . Interestingly, the viral insertions in six of the Evi3 tumors from the re-aged AKXD-27 strain cluster in a stretch of only 22 bp directly upstream of the initiation codon of the Evi3 gene (Figure 1b) , in a similar location as the viral insertions in Evi3 tumors identified by Warming et al. (2003) . Insertions at Evi3 in the initial tumors clustered within a 200 bp region as determined by Southern blot data (Justice et al., 1994) , suggesting that viral insertions in a small region are required to disrupt the normal expression of the Evi3 gene to cause leukemia.
The Evi3 transcript is encoded by eight exons and spans approximately 286 kb of genomic DNA. It shows 88% sequence similarity to EBFAZ , which is located on mouse chromosome 8. The Evi3 predicted protein is 1312 amino acids, contains 30 Kru¨ppel family zinc-fingers (Figure 1c) , and shares 63% homology to the EBFAZ predicted protein. Based on the protein sequence similarity to EBFAZ, we examined the possibility that Evi3 could be involved in B-cell differentiation through regulation of EBF activity.
Expression analysis of the Evi3 gene
Evi3 expression levels were examined in wild-type tissues, B-cell lines, and tumors from AKXD-27 animals with or without viral insertions at Evi3. Quantitative real-time PCR was used to optimize the expression analysis from RNAs made from tumor tissues. Evi3 expression has been observed in wild-type B-cells at all stages from Pro-B to mature B-cells (Warming et al., 2003) . To evaluate relative expression levels through quantitative real-time PCR, we selected one tissue sample, wild-type spleen, as our standard. Expression levels in other tissues are shown as fold changes relative to the expression level in spleen, which was designated as one. The results are shown on a logarithmic scale (Figure 2a ). We used wild-type spleen as our standard, since in most cases spleen was used to isolate tumor RNA. In wild-type tissues, Evi3 was highly expressed in adult brain, 12.5 dpc embryos, adult lung, testes, and B220 þ cells as compared to spleen (Figure 2a) . The NFS-467 cell line, which has a viral insertion at Evi3 (Justice et al., 1994) , also had higher levels of Evi3 expression relative to wild-type spleen (Figure 2a) .
We then examined Evi3 expression levels in B-cell tumors with viral insertions at Evi3 as compared to B-cell tumors without insertions in the Evi3 locus (Figure 2b and c). All tumors were from female mice. For these studies, we compared the expression levels to tumor C27-193, a Pro-B tumor without an Evi3 insertion. We chose this sample as our standard because it is the same stage as most of the Evi3 tumors, and because it is a spleen tumor with cellularity similar to the Evi3 tumors examined. In AKXD-27 tumors with insertions at Evi3, expression levels of Evi3 ranged from fourfold higher than control tumor C27-193 up to 217 times the expression level in the control tumor, with all Evi3 tumors except 27-258 showing higher expression than the control tumors. In AKXD-27 tumors without Evi3 insertions, only one tumor showed slightly elevated levels of Evi3 as compared to the control tumor C27-193 (C27-224, Figure 2c ). When the expression levels of Evi3 in the tumors with viral insertions at Evi3 are compared to the tumors without insertions, there is a dramatic upregulation of Evi3 in the tumors with viral insertions (Figure 2b and c) .
The Evi3 predicted protein shows homology to EBFAZ, a protein that interacts with EBF and negatively regulates EBF target gene transcription in the olfactory epithelium . To determine if Evi3 expression could modulate EBF activity, we examined the expression of EBF and EBFtarget genes in tumors from AKXD-27 mice with or without viral insertions at Evi3. We found that EBF was expressed in tumors with viral insertions at the Evi3 locus (Figure 2b ). The expression levels of EBF are elevated 40-185 times over levels in non-Evi3 tumor C27-193. EBF levels in control tumors without Evi3 
Genomic DNA was extracted from AKXD-27 mice (n ¼ 41) with lymphoid tumors and probed by Southern blot analysis for antigen receptor rearrangements or viral insertion mutations at Evi3. Tumors were classified based upon molecular rearrangements of receptor genes. (Smith et al., 2002) . Our study extends this finding to leukemia samples. To further examine the effect of Evi3 overexpression in AKXD-27 tumors, we analysed the expression levels of EBF-target genes in tumors with the Evi3 insertion and compared the levels to tumors without the Evi3 insertion. EBF has been demonstrated to directly regulate the transcription of mb-1 and B29, components of the pre-B-cell receptor (Hagman et al., 1993; Akerblad et al., 1999; Gisler et al., 2000) . The expression of mb-1 in Evi3 tumors (Figure 2b The expression levels of Pax-5 (also called B-cellspecific activator protein (BSAP)), another direct target of EBF (O'Riordan and Grosschedl, 1999), were analysed in Evi3 and control tumors. All Evi3 tumors show expression levels that are increased as compared to tumor C27-193, with values ranging from 100-fold to more than 1000-fold greater expression (Figure 2b ). All the control tumors have expression that is increased relative to C27-193, but the expression increase ranges from only slightly more than two times to 100 times the C27-193 level (Figure 2c) .
All of the Evi3 tumors show higher expression of EBF-target genes than control tumors, with the exception of control tumors C27-189 and C27-266, which have similar levels of mb-1and Pax-5 as the Evi3 tumors 27-207 and 27-183. However, the majority of the Evi3 tumors show upregulation of the target genes as compared to control tumors. For most of the target genes, the control tumors have expression in the range of two to 10 times the C27-193 level, while the Evi3 tumors show expression levels greater than 10-1000 times the expression levels of tumor C27-193. These results suggest that upregulation of Evi3 expression leads to increased transcription of EBF target genes through modulation of EBF activity.
Flow cytometry on Evi3 tumors
To determine the immunophenotype of tumor cells misexpressing Evi3, we reconstituted tumors by injecting cryopreserved cells from the leukemic spleen of mouse Evi3 modulates EBF activity in B-cell leukemia KE Hentges et al A16 into syngeneic mice. At 5 weeks after intraperitoneal injection of tumor cells, leukemias became visible in all mice as enlarged lymph nodes, and increased peripheral white blood cell counts. Southern blot analysis demonstrated that the reconstituted tumors maintained the viral insertions at Evi3 in mice A235, A236, and A237, but not the control littermate A234, which was not injected with tumor cells (Table 2 and data not shown).
Examination of reconstituted tumor cells by flow cytometry confirmed that they were of B-cell origin ( Figure 3 ). The control littermate A234 lymph node exhibited a normal CD4/CD8 profile, while lymph nodes from tumor-bearing mice possessed virtually no CD4 þ or CD8 þ cells (Figure 3a ). B220 þ cells were found in low numbers and Thy-1 þ cells found in high numbers in A234 control lymph nodes, whereas lymph nodes from mice A235, A236, and A237 contained almost exclusively B220 þ , Thy-1 À cells (Figure 3b) , demonstrating that the tumors are of B-cell origin.
We also assessed the tumor cells for a variety of B-cell surface markers to further localize the stage of developmental arrest (Figure 3c ). The tumor cells were negative for a variety of temporally expressed B-cell markers, including the progenitor markers CD34 and CD117, and the immature marker sIgM (data not shown). However, in addition to B220, we identified three markers, CD19, CD38, and CD24, which are expressed in high densities on the surface of reconstituted tumor cells as compared to a wild-type littermate (Figure 3c ). Both CD19 and CD38 are downstream of EBF (Lund et al., 1996; Nutt et al., 1997) , providing further evidence that increased Evi3 levels disrupts the normal EBF function.
To confirm that the increased CD19 levels were not specific to the A16 mouse we used to reconstitute the Evi3 tumors, we analysed CD19 expression by Western blot in tumor tissue from five mice with Evi3 viral insertions and two stage-matched control tumors (Figure 3d ). All the tumors were Pro-B tumors (Table 1) . We found that CD19 protein levels were elevated in the Evi3 tumors as compared to controls (Figure 3d ). Total protein was the same in all samples as demonstrated by Gapdh levels. Notably, the C27-189 tumor shows the highest CD19 protein expression of the control tumors. This same tumor also shows the highest RNA expression of EBF target genes by real-time PCR (Figure 2d ), indicating that it is consistent to observe upregulation of several EBF targets in the same tumor. This tumor does not have viral insertions near EBF or any of the known EBF target genes, although the genes affected by the viral insertion in tumor C27-189 have not been characterized (http://www.mouse-genome.bcm. tmc.edu/vstdata/). The CD19 antibody used in these experiments recognizes different phosphorylation states of CD19. Interestingly, the bands observed in the control tumor, C27-189, show faster migration than the CD19 species in the Evi3 tumors, indicating that, although CD19 protein is present in the controls, it is not highly phosphorylated. CD19 phosphorylation promotes B-cell receptor (BCR) signaling and leads ultimately to B-cell proliferation (Xu et al., 2002) ; thus, the CD19 protein isoforms present in the Evi3 tumors are consistent with increased BCR signaling due to EBF target activation.
Evi3 modulation of EBF activity
To demonstrate that Evi3 can affect EBF transcriptional activation, we performed co-transfections of EBF (Sigvardsson et al., 1997 ) and a B29 promoter-luciferase construct , which is a known target of EBF. We then co-transfected Evi3 to demonstrate that it could modulate the activation of the B29 reporter. When EBF and B29-luc are co-transfected into HEK293 cells, we see more than 10-fold upregulation of B29 activity compared to wells only transfected with the B29 reporter (Figure 4 ). Transfection of a vector control does not affect the levels of the B29-luc reporter. However, when Evi3 is added along with EBF, using the Evi3 IMAGE clone corresponding to the BC021376 sequence, we see a downregulation of B29 reporter activity to the baseline levels seen without EBF (Figure 4 ). We observed similar results when using the Evi3 image clone corresponding to the BI730849 sequence (data not shown). This is consistent with what has been reported for human Evi3 (Bond et al., 2004) .
It has been demonstrated that zinc-fingers 27-30 of the EBFAZ protein interact with EBF (Tsai and Reed, 1998) . We wanted to determine if the homologous zincfingers of Evi3 might modulate EBF transcriptional activity. We generated a deletion within the Evi3 EST BC021376 that eliminated the final six zinc-fingers of the protein. The wild-type Evi3 protein is composed of 1311 amino acids. The protein in this new construct, called BCD, contains only the first 1013 amino acids of the Evi3 protein, followed by 57 unique amino acids caused by the disruption in reading frame from the deletion. The 57 amino-acid sequence was searched against the Blast nr protein database, as well as Swissprot and pdb, and was not found to contain any conserved domains or homology to any known proteins. Co-transfection of EBF, B29-luc, and BCD demonstrated no reduction in luciferase levels when compared to transfection of EBF and B29-luc, indicating that the C-terminal portion of the Evi3 protein is required for modulation of EBF activity (Figure 4a ). The expression of Evi3 and the deletion construct BCD was confirmed by RT-PCR on cells from the transfection (Figure 4b and c) . Additionally, this demonstrates that zinc-fingers homologous to the ones that mediate the protein-protein interaction between EBFAZ and EBF are required for the interaction between Evi3 and EBF. This is the first demonstration of a functional interaction between a portion of the Evi3 protein and EBF.
Discussion
Evi3 has sequence similarity to EBFAZ/Roaz, a multiple zinc-finger protein identified through its ability to interact with Olf-1/EBF Reed, 1997, 1998) . EBFAZ contains Kru¨ppel zinc-fingers of the TFIIIA type, which can mediate protein-protein interactions as well as DNA-protein interactions (Tsai and Reed, 1998) . The EBFAZ protein interacts with SMADs in response to BMP2 signals through one group of zincfingers, while it interacts with EBF and SP-1 like GCrich DNA sites through other zinc-fingers (Hata et al., 2000) . Due to the sequence similarity of Evi3 and EBFAZ, and to previous studies localizing Evi3 to the nucleus (Warming et al., 2003) , we propose that Evi3 has a role in the development and/or differentiation of Bcells through the regulation of gene transcription ( Figure 5 ). EBFAZ has also been shown to interact with Smads to regulate mesoderm and neural development by activating the Xenopus genes Xvent-2 (Hata et al., 2000) and Xretpos (Shim et al., 2002) . Thus, it is possible that the Evi3 gene also has additional roles in the regulation of normal embryonic development. We find high levels of Evi3 expression in embryonic tissues, consistent with this theory. Additionally, we find expression of Evi3 in nontumor tissues such as brain, suggesting that Evi3 may function in those tissues to regulate Smad activity.
Our expression analysis indicates that Evi3 is upregulated in tumors due to viral insertions in the first intron of the Evi3 gene, just upstream of the coding sequence. B-cell tumors without viral insertions at Evi3 do not show overexpression of this gene, suggesting that the viral LTR drives the expression of Evi3 in tumors (Warming et al., 2003) . Evi3 has homology to EBFAZ, a protein identified by its ability to interact with EBF. We demonstrate that EBF target genes have higher Our results indicate that Evi3 interacts with EBF during B-cell leukemogenesis. EBF is a B-cell transcription factor required for the initiation of B-lymphopoiesis in the bone marrow (Schebesta et al., 2002) . Along with the basic helix-loop-helix transcription factor E2A, EBF is required for the formation of B-cells from a common lymphoid progenitor cell (reviewed in Greenbaum and Zhuang, 2002) . EBF expression induces the expression of B-cell-specific genes required for the activity of the B-cell receptor, including mb-1 and B29 (Schebesta et al., 2002) . The mb-1 and B29 genes encode the Ig-a/Ig-b heterodimer, which associates with membrane-bound Ig molecules and contains the signaling activity of the B-cell receptor (Campbell et al., 1991) . The expression of mb-1 and B29 is upregulated in tumors with retroviral insertions at Evi3 when compared to tumors without Evi3 insertions, indicating that overexpression of Evi3 leads to stimulation of EBF activity. This is in contrast to signaling in the olfactory epithelium, where EBFAZ association negatively regulates EBF function .
In addition to the regulation of mb-1 and B29, EBF also induces the expression of Pax-5/BSAP (O'Riordan and Grosschedl, 1999). Binding sites for EBF have been identified in the Pax-5 promoter, and Pro-B-cells from mice that are lacking one copy of both EBF and the Bcell transcription factor E2A fail to express Pax-5 (O'Riordan and Grosschedl, 1999) . Pax-5 is critical for the later development of B-cells, as Pax-5-deficient mice have a block in B-cell formation at the pre-B-cell stage, slightly later than the block seen in the E2A and EBF knockouts (reviewed in Maier and Hagman, 2002 ). Our results demonstrate that Pax-5 expression is also upregulated in tumors with viral insertions at Evi3. A role for Pax-5 in leukemogenesis is not unexpected, as tumors with viral insertions at the Pax-5 locus have also been identified (Suzuki et al., 2002) .
We found that the reconstituted Evi3 tumors expressed higher levels of CD19 as compared to controls. Tumors from aged AKXD27 animals with Evi3 insertions also demonstrated higher levels of CD19 protein than control tumors. The CD19/CD21 cell surface receptor complex transduces signals required for B-cell development and function (Hasegawa et al., 2001) . CD19 is a surface marker expressed throughout B-cell development, first appearing on pro-B cells (Zhou et al., 1991) . CD19-deficient mice have significantly fewer B cells in peripheral lymph nodes and spleen, impaired Bcell proliferation, and reduced serum Ig (Engel et al., 1995) . After BCR activation, CD19 phosphorylation is required to begin a cascade of signaling leading to B-cell proliferation (Xu et al., 2002; Hase et al., 2004) . Interestingly, the CD19 protein present in Evi3 tumors is more highly phosphorylated than the species found in controls, indicating that BCR signaling is activated in Evi3 tumors.
Notably, CD19 is regulated by EBF in the human (Gisler et al., 1999) . While it has not been shown to be under direct EBF control in the mouse, it is likely that EBF promotes mouse CD19 expression in B-cells, through regulation of Pax-5/BSAP signaling. Pax-5 is a target of EBF, and there are EBF-binding sites in the Pax-5 promoter (O'Riordan and Grosschedl, 1999). Additionally, Pax-5 has been demonstrated to bind to sequences in the CD19 promoter (Nutt et al., 1997) . Pax-5-deficient mice lack CD19 expression (Nutt et al., 1997) . There is further evidence that EBF and Pax-5 act in concert to regulate B-cell development. The EBF target gene, mb-1, is also a target of Pax-5 (Nutt et al., 1998) . Pre-B-cells isolated from Pax-5-deficient mice lack mb-1 expression (Nutt et al., 1998) . Promoter analysis demonstrated that EBF, E2A, and Pax-5 regulate mb-1 expression during B-cell development, with EBF and E2A controlling expression at the pre-Bcell stage, and Pax-5 promoting mb-1 expression in later stages of B-cell development . Thus, proper EBF function is required for B-cell development and function. We demonstrate here that Evi3 overexpression disrupts this pathway in tumors with Evi3 viral insertions.
CD38 has been implicated as a multi-role surface molecule differentially expressed by immature and activated cells of a variety of lineages. Interestingly, CD38 signaling requires expression of a functional Bcell receptor complex (Lund et al., 1996 (Lund et al., , 1999 DonisHernandez et al., 2001) . The B-cell receptor is encoded by the mb-1 and B29 genes, which are known targets of EBF. Thus, CD38 is likely also a downstream target of EBF. The upregulation of CD38 in reconstituted Evi3 tumors, similar to the upregulation of mb-1, B29, and CD19, is consistent with this theory.
We also demonstrate that Evi3 can modulate EBF transcriptional activity. In HEK293 cells, we observe that co-transfection of Evi3 and EBF decreases the expression of B29, an EBF-target gene. This is consistent with results for co-transfection of the human Evi3 modulates EBF activity in B-cell leukemia KE Hentges et al homolog of Evi3 (Bond et al., 2004) . We have also determined that the C-terminal region of Evi3 is required for modulation of EBF activity. Interestingly, in our tumor samples, we see upregulation of EBF targets when Evi3 expression increases. Although HEK293 cells do express Evi3 (Bond et al., 2004) , it is possible that in kidney cells there are other factors that cause downregulation of EBF targets, contrary to the results shown in B-leukemia cells. In wild-type kidney cells, we do detect Evi3 expression at a level higher than wild-type spleen, indicating that Evi3 must have some function in this tissue unrelated to lymphoid differentiation. Thus, perhaps in nonleukemic tissues, Evi3 expression leads to a downregulation of EBF target genes, while in leukemogenic cells Evi3 expression leads to upregulation of EBF targets.
Evi3 transcripts have been detected in several lymphomatous pro-B and pre-B lines, but are missing in an immature B-cell line (Justice et al., 1994) , suggesting that Evi3 is differentially regulated in B-cell development. It is likely that Evi3 controls temporal events in early B-cell lymphopoeisis, which regulate the EBF differentiation pathway, and its abnormal expression may alter normal developmental processes to lead to the development of leukemias. Several downstream targets of EBF activity are upregulated in Evi3 tumors, indicating that Evi3 can modulate EBF transcriptional activity. While mice that lack functional EBF pathway members fail to produce B-cells (reviewed in Greenbaum and Zhuang, 2002; Maier and Hagman, 2002) , this study suggests that activation of EBF targets through increased Evi3 expression can cause B-cell leukemia.
Materials and methods
Mice AKXD-27 recombinant inbred mice have been described elsewhere (Mucenski et al., 1986; Justice et al., 1994) . Mice were aged and sacrificed as tumors became apparent. Mice failing to show disease manifestations by 14 months were killed and examined for tumors.
Tumor processing
Tumors for DNA were removed from mice and snap-frozen in liquid nitrogen. Single-cell suspensions of tumors were made by gently disrupting tumors in Hank's balanced salt solution (HBSS; Life Technologies, Bethesda, MD, USA; Schountz et al., 1996) . Cells were resuspended in tumor medium at 10 6 cells/ml, then tissue culture grade DMSO (Sigma) was added to 10% v/v. Cells were stored frozen in liquid nitrogen.
Southern blot analysis
High molecular weight DNA was prepared from snap-frozen tumors described above (Mucenski et al., 1986) . Restriction enzyme digestion to detect rearrangements at the IgH (EcoRI), Igk (BglII), TCR Jb1 (PvuII), Jb2 (HindIII), and Evi3 (XbaI) loci and Southern hybridization have been detailed elsewhere (Gilbert et al., 1993; Justice et al., 1994) . Probes for IgH, Igk, TCR Jb1, and Jb2 have been described elsewhere (Kronenberg et al., 1985; Mucenski et al., 1986) . The probe for Evi3 was prepared from a 1 kb KpnI genomic fragment cloned into pBluescript KS þ (Justice et al., 1994) . Radiolabeled probes were synthesized with a Prime-Itt kit according to the manufacturer's directions (Stratagene, La Jolla, CA, USA).
EST clone sequencing
EST clones were purchased from Research Genetics (Huntsville, AL, USA). Cycle sequencing was performed with the ABI Big Dye sequencing kit according to the manufacturer's instructions using standard sp6 and T7 oligo primers. Sequencing reactions were analysed in the Baylor College of Medicine Department of Molecular and Human Genetics Sequencing Core. Analysis of DNA sequence was performed using Sequencher 4.1 software (Gene Codes Corp., Ann Arbor, MI, USA).
Protein sequence analysis
Evi3 and EBFAZ protein sequence alignments were performed using clustalw (http://www.ebi.ac.uk/clustalw). Protein sequences were also analysed with Interpro scan to identify conserved domains (http://www.ebi.ac.uk/interpro/scan.html).
Real-time PCR analysis
RNA extraction Total RNA was extracted from the tissues using RNA STAT-60 total RNA/mRNA isolation reagent according to the manufacturer's instructions (Tel-Test, Inc., Friendswood, TX, USA). The RNA pellet was dissolved in 40 ml of DEPC-water and treated with DNase I, amplification grade (Invitrogen) for 30 min at 371C.
Reverse transcription ABI Reverse Transcription kits were used for generating cDNA. In all, 2 mg of RNA was added to a reaction containing 1 Â RT buffer, 5.5 mM MgCl 2 , 500 mM per dNTP, 2.5 mM random hexamers, 0.4 U/ml RNase inhibitor, and 3.125 U/ml Multiscribe Reverse Transcriptase, for a total reaction volume of 100 ml. The RT thermal cycling parameters used for samples with random hexamers were 251C for 10 min, 371C for 60 min, and 951C for 5 min.
Real-time quantitative PCR All primers were optimized on the ABI 7000 SDS using the SYBR Green dye. All samples for quantitative PCR were run in triplicates. In all, 1 ml of the cDNA was added to the optimal mix of the forward and reverse primers and 1 Â SYBR Green PCR master mix to get a final reaction volume of 50 ml. The following thermal cycling parameters were used for quantitative PCR using ABI 7000 SDS: 951C for 10 min, 40 cycles of 951C for 15 s, and 601C for 1 min.
Data analysis Real-time PCR was analysed using relative expression levels (Bieche et al., 2001) . Expression of the genes was compared to both an endogenous RNA control, 18S RNA, and to levels in wild-type spleen as a tissue control for the tumors, similar to the method described by Bieche et al (2001 
Reconstitution of tumors
Frozen single tumor-cell suspensions were quick-thawed at 371C. Cells were washed 2 Â with tumor medium, then 3 Â in sterile PBS. Cells were adjusted to 5 Â 10 7 /ml and 200 ml was injected intraperitoneally into 12-week-old sex-matched AKXD-27 mice. Tumors appeared in 5 weeks and mice were processed as described above.
Flow cytometry
Cells were washed and adjusted to 2 Â 10 6 /ml in wash buffer (5% FBS-PBS), and 100 ml pipetted into the wells of V-bottom 96-well microtiter plates (Nunc). Plates were centrifuged to pellet cells, supernatants decanted and cells resuspended by gentle vortexing. Wash buffer containing antibody conjugates (Pharmingen) was added to the wells, followed by incubation on ice for 45 min. Antibodies used were to CD4 (RM4-4), CD8a (53-6.7), CD19 (1D3), CD24 (M1/69), CD34 (RAM34/49E8), CD38 (90), CD117 (2B8), B220 (cat #553086), and Thy1 (cat #553013). Cells were washed twice, then fixed in 1% paraformaldehyde, and 10 000 events collected with a FACStar flow cytometer (Becton-Dickinson) as described previously (Schountz et al., 1996) .
Western blot
Tumor tissue was homogenized in RIPA protein lysis buffer. Membrane blocking and antibody incubations were performed according to the manufacturer's protocol for anti-CD19 (1 : 500 dilution, cat #3574, Cell Signaling Technology), and anti-Gapdh (1 : 2500 dilution, clone 6C5, Advanced Immunochemical). Protein expression was visualized using the ECL Western Blotting Analysis System (RPN-2108, Amersham Biosciences) according to the manufacturer's instructions.
Cell culture and transfection
HEK293 cells were cultured in RPMI 1640 medium with Lglutamine (Invitrogen), 50 mM HEPES, and 10% FBS. Transfections were carried out using 100 ng of pMDEBF (myc-EBF), pMDCDNA (myc tag vector), pBC (Evi3 clone #BC021376), pBCD (Evi3 clone #BC021376 with a deletion between bases 3087 and 3796), and pB29-luc (B29 reporter) plasmids with 20 ng of pRLCMV for a transfection efficiency control and 1 ml FuGene (roche) lipfection reagent in a six-well plate format. Luciferase assays were performed using the Dual Luciferase Assay Kit (Promega) with normalization to renilla luciferase to control for transfection efficiency. All transfections were repeated at least four times. To confirm that the BC and BCD constructs were expressed in the transfections, half of the cells were removed from each well and used to prepare RNA (Wizard kit, Promega) and then reverse transcribed into cDNA (ABI reverse transcription kit). RT-PCR was performed with primers that span the deleted region of the Evi3 gene (BC for: tggataccggaaactgtcgta, BC rev: ggagtctgtctatctggtgct). For each luciferase cell culture transfection experiment, normalized luminescence readings were divided by the average luminescence readings from cells co-transfected with myc-EBF and B29-luciferase. These values are expressed as a percentage of myc-EBF and B29-luciferase co-transfection. The BCD construct was generated by digesting BC021376 with Bsu36I and BstBI. This removed an approximately 700 bp fragment from the construct. The ends of the construct were filled in, and a blunt ligation was performed. The correct ligation of the ends was verified by sequencing (primer sequence: tggataccggaaactgtcgta). Plasmids were purified for transfection using a midi-prep kit (Qiagen).
